ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Danazol: Pediatric drug information

Danazol: Pediatric drug information
2024© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Danazol: Drug information" and "Danazol: Patient drug information"

For abbreviations, symbols, and age group definitions show table
ALERT: US Boxed Warning
Thromboembolic events:

Thromboembolism, thrombotic and thrombophlebitic events, including sagittal sinus thrombosis and life-threatening or fatal strokes have been reported.

Pregnancy:

Use of danazol in pregnancy is contraindicated. A sensitive test (eg, beta subunit test if available) capable of determining early pregnancy is recommended immediately prior to start of therapy. Additionally, a nonhormonal method of contraception should be used during therapy. If a patient becomes pregnant while taking danazol, administration of the drug should be discontinued and the patient should be apprised of the potential risk to the fetus. Exposure to danazol in utero may result in androgenic effects on the female fetus; reports of clitoral hypertrophy, labial fusion, urogenital sinus defect, vaginal atresia, and ambiguous genitalia have been received.

Hepatic effects:

Experience with long-term therapy with danazol is limited. Peliosis hepatis and benign hepatic adenoma have been observed with long-term use. Peliosis hepatis and hepatic adenoma may be silent until complicated by acute, potentially life-threatening intra-abdominal hemorrhage. The physician therefore should be alert to this possibility. Attempts should be made to determine the lowest dose that will provide adequate protection. If danazol was begun at a time of exacerbation of hereditary angioneurotic edema due to trauma, stress or other cause, periodic attempts to decrease or withdraw therapy should be considered.

Intracranial hypertension:

Danazol has been associated with several cases of benign intracranial hypertension also known as pseudotumor cerebri. Early signs and symptoms of benign intracranial hypertension include papilledema, headache, nausea and vomiting, and visual disturbances. Patients with these symptoms should be screened for papilledema and, if present, the patients should be advised to discontinue danazol immediately and be referred to a neurologist for further diagnosis and care.

Brand Names: Canada
  • Cyclomen
Therapeutic Category
  • Androgen
Dosing: Pediatric
Hereditary angioedema, prophylaxis

Hereditary angioedema, prophylaxis (alternate agent): Limited data available:

Short-term prophylaxis (for patient-specific triggers, medical and dental procedures):

Note: For planned procedures, on-demand therapy with C1-inhibitor concentrate is preferred; however, if not available, danazol may be considered if time allows adequate therapy before procedure or if patient uses danazol as long-term prophylaxis (Ref):

Postpubescent Children and Adolescents: Oral: 2.5 to 10 mg/kg/day divided into 3 doses; maximum daily dose: 600 mg/day; begin at least 5 to 7 days prior and continue for 2 to 5 days post-procedure (Ref).

Long-term prophylaxis:

Note: Use is not recommended in children due to potential adverse effects on bone, growth, and sexual development (Ref). Danazol is not a preferred first-line agent; use should be reserved for situations when C1-inhibitor concentrate (first-line) are not available or patient preference for oral therapy (Ref):

Adolescents ≥16 years: Oral: Initial: 2.5 mg/kg/day; maximum initial daily dose: 50 mg/day; increase slowly every 2 weeks until symptoms controlled, or maximum tolerated or maximum recommended dose is reached; maximum daily dose: 5 mg/kg/day up to 200 mg/day. Once control is obtained, reduce interval to every other day or every third day; maximum dose: 100 mg/dose (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Use is contraindicated in patients with markedly impaired renal function.

Dosing: Hepatic Impairment: Pediatric

Use is contraindicated in patients with markedly impaired hepatic function.

Dosing: Adult

(For additional information see "Danazol: Drug information")

Endometriosis

Endometriosis (alternative agent):

Note: For use as an alternative to other first-line therapies in patients with pain associated with endometriosis (Ref).

Initial:

Mild disease: Oral: 200 to 400 mg/day in 2 divided doses.

Moderate to severe disease or infertility due to endometriosis: Oral: 800 mg/day in 2 divided doses.

Dosage adjustment: Gradually reduce dosage to maintain amenorrhea.

Duration of therapy: Continue therapy uninterrupted for 3 to 6 months; may extend up to 9 months, if needed. If symptoms recur following discontinuation, may reinitiate treatment.

Fanconi anemia

Fanconi anemia (alternative agent) (off-label use): Oral: Initial: ~3 to 7.7 mg/kg/day; if response observed, may gradually taper dose to ~65% of original dose after ~2 years, and further taper to ~54% after another year (Ref).

Hereditary angioedema, prophylaxis

Hereditary angioedema, prophylaxis (alternative agent):

Note: May be considered as an alternative to other first-line therapies for preprocedural (short-term) and long-term hereditary angioedema (HAE) attack prophylaxis. Danazol is not recommended for treatment of acute HAE attacks (Ref).

Preprocedural (short-term) prophylaxis (off-label dose): Oral: 400 to 600 mg/day (Ref). Administer for 5 days before and for 2 to 3 days after procedure; frequent short courses may lead to adverse effects associated with long-term use (Ref).

Long-term prophylaxis: Oral: Initial: 100 to 200 mg once daily (Ref). After favorable initial response, decrease the dosage by 50% or less at intervals of 1 to 3 months or longer if the frequency of attacks dictates; if an attack occurs, increase the daily dosage by up to 200 mg/day. Usual dosage range: 100 mg every other day to 200 mg 3 times daily (Ref). Note: Use the minimum effective dose; use of dosages >200 mg/day for an extended time is not recommended due to adverse effects (Ref).

Immune thrombocytopenia, refractory

Immune thrombocytopenia, refractory (off-label use):

Note: May be considered in patients whose symptoms are refractory to or who are unable to take other preferred agents (Ref).

Oral: 200 mg 2 to 4 times/day; approximate time to response is 3 to 6 months (Ref) or 600 mg once daily for at least 6 months followed by 400 mg once daily for 3 months, then (if remission maintained) 200 mg once daily (Ref).

Mastalgia, cyclic, severe

Mastalgia, cyclic, severe (off-label use):

Note: For use in patients with severe or refractory cyclic breast pain associated with benign breast disorders (Ref).

Oral: 200 mg/day administered in 1 or 2 divided doses. Cyclic administration during the luteal phase of the menstrual cycle (days 14 to 28) may reduce the risk of adverse effects; if given continuously, initiate the first day of the menstrual cycle (Ref). Usual dosage range: 100 to 200 mg/day; doses up to 400 mg/day have been studied but may be associated with a higher incidence of adverse effects (Ref).

Duration of therapy: 3 to 6 months (Ref). In some studies in patients receiving continuous (ie, not cyclic) therapy, the dose was tapered off prior to discontinuation (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling. Use is contraindicated in patients with markedly impaired renal function.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling. Use is contraindicated in patients with markedly impaired hepatic function.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

Postmarketing:

Cardiovascular: Acute myocardial infarction (Boos 2003), edema, flushing, increased blood pressure, palpitations, syncope, tachycardia, thrombosis (including thromboembolic complications and thromboembolism [cerebrovascular accident, sagittal sinus thrombosis]) (Alvarado 2001)

Dermatologic: Acne vulgaris, alopecia (Duff 1981), diaphoresis, erythema multiforme (Reynolds 1992), maculopapular rash, papular rash, pruritus, purpuric rash, seborrhea, skin photosensitivity, Stevens-Johnson syndrome (Koh 2015), urticaria, vesicular eruption

Endocrine & metabolic: Altered serum glucose (including abnormal glucose tolerance test) (Williams 1985), change in libido, changes in serum lipids (including decreased HDL cholesterol and increased LDL cholesterol) (Luciano 1983), decreased sex hormone binding globulin (Forbes 1986), decreased thyroxine binding globulin, exacerbation of porphyria (Lamon 1979), fluid retention, hirsutism (Zawar 2004), increased sex hormone-binding globulin, increased thyroxine binding globulin, menstrual disease (amenorrhea, irregular menses, spotty menstruation), weight gain

Gastrointestinal: Change in appetite, constipation, gastroenteritis, gingival hemorrhage, nausea, pancreatitis (Balasch 1994), vomiting

Genitourinary: Breast atrophy, clitoromegaly, decreased ejaculate volume, hematuria, inhibition of spermatogenesis, nipple discharge, pelvic pain, spermatozoa disorder (including changes in asthenospermia, semen viscosity, and sperm count), vaginal dryness, vaginal irritation

Hematologic & oncologic: Abnormal erythrocytes (increased) (Barton 1987), change in serum protein, eosinophilia, leukocytosis, leukopenia, petechial rash, polycythemia, purpuric disease (splenic peliosis) (Arai 2007), thrombocythemia, thrombocytopenia (Yamamoto 1997)

Hepatic: Hepatic adenoma (Middleton 1989), hepatic failure (Hayashi 2001), hepatic neoplasm (malignant; after prolonged use; hepatocellular neoplasm) (Berkel 2014), hepatotoxicity (idiosyncratic) (Chalasani 2014), increased liver enzymes, jaundice (including cholestatic jaundice and hepatocellular jaundice) (Qaseem 1992), peliosis hepatitis (Makdisi 1995)

Nervous system: Anxiety, asthenia, chills, depression, dizziness, emotional lability, fatigue, Guillain-Barre syndrome (Hory 1985), headache, intracranial hypertension (Tan 2019), nervousness, paresthesia, seizure, sleep disorder, voice disorder (deepening of the voice, hoarseness, instability, sore throat), tremor

Neuromuscular & skeletal: Arthralgia, back pain, increased creatine phosphokinase in blood specimen, joint swelling, limb pain, muscle cramps, muscle spasm, myalgia, neck pain

Ophthalmic: Cataract, visual disturbance

Respiratory: Interstitial pneumonitis, nasal congestion

Miscellaneous: Fever

Contraindications

Hypersensitivity to danazol or any component of the formulation; undiagnosed abnormal genital bleeding; pregnancy; breastfeeding; porphyria; markedly impaired hepatic, renal, or cardiac function; androgen-dependent tumor; active or history of thrombosis or thromboembolic disease

Canadian labeling: Additional contraindications (not in the US labeling): Genital neoplasia; concomitant administration with simvastatin.

Warnings/Precautions

Concerns related to adverse effects:

• Androgenic effects: May cause nonreversible androgenic effects.

• Blood lipid changes: Anabolic steroids may cause blood lipid changes (decreased high density lipoproteins and increased low density lipoproteins) with increased risk of arteriosclerosis and coronary artery disease.

Disease-related concerns:

• Cyclic breast pain (mastalgia) associated with benign breast disorders: Use is reserved for severe and refractory cases that have not responded to conservative measures and analgesics. Malignancy should be ruled out prior to therapy (ACOG 2016; Groen 2017).

• Diabetes: Use with caution in patients with diabetes mellitus; insulin requirements may be increased; monitor carefully.

• Edematous conditions: Use with caution in patients with conditions influenced by edema (eg, cardiovascular disease, migraine, seizure disorder, renal impairment); danazol may cause fluid retention.

• Porphyria: May cause exacerbations of acute intermittent porphyria; use is contraindicated in patients with porphyria.

Other warnings/precautions:

• Appropriate use: Endometriosis: Danazol is generally reserved for the treatment of pain associated with endometriosis when other agents are not available, due to its high incidence of adverse events (Dunselman 2014).

Warnings: Additional Pediatric Considerations

Due to irreversible androgenic side effects, danazol should be avoided in prepubescent pediatric patients and exposure in adolescents should be limited; in adolescents, assess risk versus benefit; monitor patients closely (Laufer 2008; US HAEA [Busse 2021]; WAO [Craig 2012]; Zuraw 2013b).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

Generic: 50 mg, 100 mg, 200 mg

Generic Equivalent Available: US

Yes

Pricing: US

Capsules (Danazol Oral)

50 mg (per each): $3.63

100 mg (per each): $5.44

200 mg (per each): $10.29 - $12.00

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

Cyclomen: 50 mg, 100 mg, 200 mg

Administration: Pediatric

Oral: Administer consistently with regard to food.

Administration: Adult

Endometriosis: Initiate therapy during menstruation or ensure patient is not pregnant while on therapy.

Storage/Stability

Store at 20°C to 25°C (68°F to 77°F). Protect from light.

Use

Treatment of endometriosis amenable to hormonal management; prevention of attacks of hereditary angioedema of all types (cutaneous, abdominal, laryngeal) (All indications: FDA approved in adults).

Medication Safety Issues
Sound-alike/look-alike issues:

Danazol may be confused with Dantrium

High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs (contraindicated in pregnancy) which have a heightened risk of causing significant patient harm when used in error (High-Alert Medications in Community/Ambulatory Care Settings).

Metabolism/Transport Effects

Inhibits CYP3A4 (weak)

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program

Ajmaline: Androgens may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. Risk C: Monitor therapy

ALPRAZolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ALPRAZolam. Risk C: Monitor therapy

Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Atorvastatin: Danazol may increase the serum concentration of Atorvastatin. Risk C: Monitor therapy

C1 inhibitors: Androgens may enhance the thrombogenic effect of C1 inhibitors. Risk C: Monitor therapy

CarBAMazepine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of CarBAMazepine. Risk C: Monitor therapy

Corticosteroids (Systemic): May enhance the fluid-retaining effect of Androgens. Risk C: Monitor therapy

CycloSPORINE (Systemic): Androgens may enhance the hepatotoxic effect of CycloSPORINE (Systemic). Androgens may increase the serum concentration of CycloSPORINE (Systemic). Management: Consider avoiding concomitant use of androgens and cyclosporine. If concomitant use is unavoidable, monitor serum cyclosporine concentrations and for signs and symptoms of hepatotoxicity. Cyclosporine dose reductions may be required. Risk D: Consider therapy modification

Dofetilide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. Risk C: Monitor therapy

Finerenone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Finerenone. Risk C: Monitor therapy

Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. Risk C: Monitor therapy

Hypertension-Associated Agents: May enhance the hypertensive effect of Androgens. Risk C: Monitor therapy

Ixabepilone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ixabepilone. Risk C: Monitor therapy

Lemborexant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lemborexant. Management: The maximum recommended dosage of lemborexant is 5 mg, no more than once per night, when coadministered with weak CYP3A4 inhibitors. Risk D: Consider therapy modification

Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide. Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day. Risk D: Consider therapy modification

Lovastatin: Danazol may increase the serum concentration of Lovastatin. Management: Initiate immediate release lovastatin at a dose of 10 mg/day, and do not exceed 20 mg/day for immediate or extended release lovastatin, in patients receiving danazol. Monitor closely for signs of lovastatin toxicity (eg, myositis, rhabdomyolysis). Risk D: Consider therapy modification

Midazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Midazolam. Risk C: Monitor therapy

NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. Risk C: Monitor therapy

Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. Risk X: Avoid combination

Red Yeast Rice: Danazol may increase the serum concentration of Red Yeast Rice. Management: Initiate red yeast rice at a dose equivalent to lovastatin 10 mg/day, and do not exceed 20 mg/day, in patients receiving danazol. Monitor closely for signs of lovastatin toxicity (eg, myositis, rhabdomyolysis). Risk D: Consider therapy modification

Simvastatin: Danazol may increase the serum concentration of Simvastatin. Risk X: Avoid combination

Sirolimus (Conventional): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Conventional). Risk C: Monitor therapy

Sirolimus (Protein Bound): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Protein Bound). Management: Reduce the dose of protein bound sirolimus to 56 mg/m2 when used concomitantly with a weak CYP3A4 inhibitor. Risk D: Consider therapy modification

Tacrolimus (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Tacrolimus (Systemic). Risk C: Monitor therapy

Triazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Triazolam. Risk C: Monitor therapy

Ubrogepant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ubrogepant. Management: In patients taking weak CYP3A4 inhibitors, the initial and second dose (given at least 2 hours later if needed) of ubrogepant should be limited to 50 mg. Risk D: Consider therapy modification

Vitamin D Analogs: Danazol may enhance the hypercalcemic effect of Vitamin D Analogs. Risk C: Monitor therapy

Vitamin K Antagonists (eg, warfarin): Androgens may enhance the anticoagulant effect of Vitamin K Antagonists. Management: Monitor for increased effects of vitamin K antagonists if an androgen is initiated/dose increased, or decreased effects if androgen is discontinued/dose decreased. Significant reductions in vitamin K antagonist dose are likely required. Risk D: Consider therapy modification

Food Interactions

Food delays time to peak levels. A high-fat meal increases plasma concentration and extent of availability.

Reproductive Considerations

Evaluate pregnancy status prior to use in patients who may become pregnant. A sensitive test capable of determining early pregnancy is recommended immediately prior to start of therapy (eg, beta subunit test, if available). A nonhormonal method of contraception should be used during therapy.

Menstrual disturbances may occur during therapy. Although ovulation may return within 60 to 90 days once danazol is discontinued, persistent amenorrhea may occur. Spermatogenesis and abnormalities in semen volume, viscosity, count, and motility may occur with long-term therapy.

Pregnancy Considerations

Androgens cross the placenta (US HAEA [Busse 2021]; WAO/EAACI [Maurer 2022]).

Exposure to danazol in utero may result in androgenic effects on the female fetus; reports of clitoral hypertrophy, labial fusion, urogenital sinus defect, vaginal atresia, and ambiguous genitalia have been received.

Use of danazol in pregnancy is contraindicated. If a patient becomes pregnant while taking danazol, administration of the drug should be discontinued, and the patient should be apprised of the potential risk to the fetus.

The use of danazol for the management of hereditary angioedema (HAE) in pregnancy that is not responsive to preferred therapy has been described in case reports (Altman 2006; Boulos 1994; González-Quevedo 2016; Milingos 2009). However, danazol is contraindicated during pregnancy; current guidelines recommend use of agents other than danazol to treat HAE in pregnant patients. Patients with HAE should be monitored closely during pregnancy and for at least 72 hours after delivery (WAO/EAACI [Maurer 2022]).

Monitoring Parameters

Liver and renal function tests (periodically); hematologic parameters; lipid panel. Signs and symptoms of intracranial hypertension (eg, papilledema, headache, nausea, vomiting), androgenic changes, and/or fluid retention; pregnancy status.

Hereditary angioedema, long-term prophylaxis: CBC, urinalysis, LFTs, and lipid profile (baseline, every 6 months while on therapy, and 6 months after discontinuation); liver ultrasound (baseline and annually); blood pressure (every 6 months); weight, signs of virilization (every 6 months) (US HAEA [Busse 2021]; WAO [Craig 2012]).

Mechanism of Action

Suppresses pituitary output of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), resulting in regression and atrophy of normal and ectopic endometrial tissue; decreases rate of growth of abnormal breast tissue; reduces attacks associated with hereditary angioedema by increasing levels of C4 component of complement

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Immune thrombocytopenia (off-label use): Initial response: 14 to 90 days; Peak response: 28 to 180 days (Neunert 2011)

Metabolism: Extensively hepatic, primarily to 2-hydroxymethyl danazol and ethisterone

Half-life elimination: 9.7 ± 3.29 hours (variable; up to 24 hours following long-term use for endometriosis)

Time to peak, serum: 4 hours (range: 2 to 8 hours)

Excretion: Urine and feces

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Danocrine | Danol;
  • (AR) Argentina: Ladogal;
  • (AT) Austria: Danokrin;
  • (AU) Australia: Azol | Danocrine;
  • (BD) Bangladesh: Danamet | Danodiol | Danzol | Gonablok | Lozana;
  • (BE) Belgium: Danatrol;
  • (BG) Bulgaria: Danoval;
  • (BR) Brazil: Ladogal;
  • (CH) Switzerland: Danatrol;
  • (CL) Chile: Danogar;
  • (CO) Colombia: Cipladanogen | Danagin | Ladogal;
  • (CZ) Czech Republic: Anargil | Danatrol | Danol | Danoval;
  • (DE) Germany: Danazol-ratiopharm | Winobanin;
  • (DO) Dominican Republic: Ladogal;
  • (EC) Ecuador: Danodiol | Ladogal;
  • (EE) Estonia: Danatrol | Danol;
  • (EG) Egypt: Danol;
  • (ES) Spain: Danatrol;
  • (FI) Finland: Danatrol | Danocrine;
  • (FR) France: Danatrol;
  • (GB) United Kingdom: Danazol cox | Danazol kent | Danazol sterwin | Danol;
  • (GR) Greece: Danatrol;
  • (HK) Hong Kong: Anargil | Danocrine | Ectopal;
  • (HR) Croatia: Danoval;
  • (HU) Hungary: Danoval;
  • (ID) Indonesia: Azol | Danocrene | Danocrine;
  • (IE) Ireland: Danatrol | Danol;
  • (IL) Israel: Danocrine;
  • (IN) India: Danogen | Danozec | Endometryl | Gonablok | Gynadom | Gynazol | Gynodan | Gynol | Ladogal | Zendol;
  • (IT) Italy: Danatrol;
  • (JO) Jordan: Danol;
  • (JP) Japan: Anason | Anason choseido | Baxal | Belrinat | Bonzol | Dainazol | Danan | Danazol maruko | Danazol Nichiiko | Danazolen | Danazorik | Danazorik choseido | Esdelart | Hosebon | Oyslon | Sofunarin | Them;
  • (KR) Korea, Republic of: Danocil | Danocrin | Danocrine | Danzocurine | Unidana | Youngpoong danazol;
  • (KW) Kuwait: Danol;
  • (LB) Lebanon: Danocrine;
  • (LT) Lithuania: Danogen | Danol | Danoval | Danozolis;
  • (LU) Luxembourg: Danatrol;
  • (LV) Latvia: Danatrol | Danogen | Danol | Danoval;
  • (MA) Morocco: Danatrol;
  • (MX) Mexico: Danalem | Ladogal;
  • (MY) Malaysia: Anargil | Azol | Danzol | Duozol | Ladogal | Nazol | Vabon;
  • (NG) Nigeria: Danal;
  • (NL) Netherlands: Danatrol;
  • (NO) Norway: Danatrol | Danazol-ratiopharm | Danocrine | Danol;
  • (NZ) New Zealand: Azol | Cyclomen | D-Zol | Danatrol | Danocrine;
  • (PE) Peru: Ladogal;
  • (PH) Philippines: Ladogal;
  • (PK) Pakistan: Danatris | Danaxy | Danocrine | Danzol | Depest;
  • (PL) Poland: Danol;
  • (PR) Puerto Rico: Danocrine;
  • (PT) Portugal: Danatrol | Danol | Mastodanatrol;
  • (QA) Qatar: Danol;
  • (RO) Romania: Danol | Danoval;
  • (RU) Russian Federation: Danogen | Danol | Danoval;
  • (SA) Saudi Arabia: Danol;
  • (SG) Singapore: Azol | Ladogal;
  • (SI) Slovenia: Danoval;
  • (SK) Slovakia: Anargil | Danol | Danoval;
  • (TH) Thailand: Anargil | Danodiol | Ectopal | Ladogal | Vabon;
  • (TN) Tunisia: Danatrol;
  • (TR) Turkey: Danasin | Danatrol;
  • (TW) Taiwan: Cyclolady | Danal | Danalol | Danodiol | Danol | Danonice | Dorink | Ectopal | Kodazol | Ladogal | Lazol | Syntozal | Unazol;
  • (UA) Ukraine: Danol | Danoval;
  • (UY) Uruguay: Ladogal;
  • (VE) Venezuela, Bolivarian Republic of: Ladogal;
  • (VN) Viet Nam: Kupdina | Puyol;
  • (ZA) South Africa: Danogen | Ladazol
  1. Alvarado RG, Liu JY, Zwolak RM. Danazol and limb-threatening arterial thrombosis: two case reports. J Vasc Surg. 2001;34(6):1123-1126. doi:10.1067/mva.2001.118078 [PubMed 11743571]
  2. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology (ACOG). Practice Bulletin No. 114: Management of endometriosis. Obstet Gynecol. 2010;116(1):223-236. doi:10.1097/AOG.0b013e3181e8b073 [PubMed 20567196]
  3. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology (ACOG). Practice Bulletin No. 164: Diagnosis and Management of Benign Breast Disorders. Obstet Gynecol. 2016;127(6):e141-e156. doi: 10.1097/AOG.0000000000001482. [PubMed 27214189]
  4. Arai S, Asai T, Uozaki H, et al. Splenic peliosis in a patient with aplastic anemia during danazol therapy. Int J Hematol. 2007;86(4):329-332. doi:10.1532/IJH97.07078 [PubMed 18055339]
  5. Balasch J, Martinez-Román S, Carreras J, Vanrell JA. Acute pancreatitis associated with danazol treatment for endometriosis. Hum Reprod. 1994;9(6):1163-1165. doi:10.1093/oxfordjournals.humrep.a138651 [PubMed 7962394]
  6. Barton IK, Mansell MA. Erythrocytosis induced by danazol in an anephric patient. Br Med J (Clin Res Ed). 1987;294(6572):615. doi:10.1136/bmj.294.6572.615 [PubMed 3103832]
  7. Boos CJ, Dawes M, Jones R, Farrell T. Danazol treatment and acute myocardial infarction. J Obstet Gynaecol. 2003;23(3):327-328. doi:10.1080/01443610310000106064 [PubMed 12918508]
  8. Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-150.e3. doi:10.1016/j.jaip.2020.08.046 [PubMed 32898710]
  9. Caballero T, Farkas H, Bouillet L, et al, "International Consensus and Practical Guidelines on the Gynecologic and Obstetric Management of Female Patients With Hereditary Angioedema Caused by C1 Inhibitor Deficiency," J Allergy Clin Immunol, 2012, 129(2):308-20. [PubMed 22197274]
  10. Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950-966. [PubMed 24935270]
  11. Craig T, Aygören-Pürsün E, Bork K, et al. WAO guideline for the management of hereditary angioedema. World Allergy Organ J. 2012;5(12):182-199. doi: 10.1097/WOX.0b013e318279affa. [PubMed 23282420]
  12. Cyclomen (danazol) [product monograph]. Laval, Quebec, Canada: Sanofi-aventis Canada Inc.; May 2017.
  13. Danazol [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc; April 2018.
  14. Danazol [prescribing information]. Philadelphia, PA: Lannett Company; September 2019.
  15. Daou S, Federici L, Zimmer J, Maloisel F, Serraj K, Andrès E. Idiopathic thrombocytopenic purpura in elderly patients: a study of 47 cases from a single reference center. Eur J Intern Med. 2008;19(6):447-451. [PubMed 18848179]
  16. Döberl A, Tobiassen T, Rasmussen T. Treatment of recurrent cyclical mastodynia in patients with fibrocystic breast disease. A double-blind placebo-controlled study—the Hjørring project. Acta Obstet Gynecol Scand Suppl. 1984;123:177-184. [PubMed 6388218]
  17. Duff P, Mayer AR. Generalized alopecia: an unusual complication of danazol therapy. Am J Obstet Gynecol. 1981;141(3):349-350. doi:10.1016/s0002-9378(16)32645-x [PubMed 7282815]
  18. Dunselman GA, Vermeulen N, Becker C, et al; European Society of Human Reproduction and Embryology. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29(3):400-412. doi:10.1093/humrep/det457. [PubMed 24435778]
  19. Farkas H, Martinez-Saguer I, Bork K, et al; HAWK. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy. 2017;72(2):300-313. doi: 10.1111/all.13001. [PubMed 27503784]
  20. Forbes KL, Dowsett M, Rose GL, Mudge JE, Jeffcoate SL. Dosage-related effects of danazol on sex hormone binding globulin and free and total androgen levels. Clin Endocrinol (Oxf). 1986;25(5):597-605. doi:10.1111/j.1365-2265.1986.tb03614.x [PubMed 3304725]
  21. González-Quevedo T, Larco JI, Marcos C, et al. Management of pregnancy and delivery in patients with hereditary angioedema due to C1 inhibitor deficiency. J Investig Allergol Clin Immunol. 2016;26(3):161-167. doi: 10.18176/jiaci.0037. [PubMed 27326983]
  22. Groen JW, Grosfeld S, Bramer WM, Ernst MF, Mullender MM. Cyclic and non-cyclic breast-pain: A systematic review on pain reduction, side effects, and quality of life for various treatments. Eur J Obstet Gynecol Reprod Biol. 2017;219:74-93. doi: 10.1016/j.ejogrb.2017.10.018. [PubMed 29059585]
  23. Hayashi T, Takahashi T, Minami T, et al. Fatal acute hepatic failure induced by danazol in a patient with endometriosis and aplastic anemia. J Gastroenterol. 2001;36(11):783-786. doi:10.1007/s005350170022 [PubMed 11757752]
  24. Hinton CP, Bishop HM, Holliday HW, Doyle PJ, Blamey RW. A double-blind controlled trial of danazol and bromocriptine in the management of severe cyclical breast pain. Br J Clin Pract. 1986;40(8):326-330. [PubMed 3527249]
  25. Hory B, Blanc D, Boillot A, Panouse-Perrin J. Guillain-Barré syndrome following danazol and corticosteroid therapy for hereditary angioedema. Am J Med. 1985;79(1):111-114. doi:10.1016/0002-9343(85)90553-4 [PubMed 4014294]
  26. Kishino Y, Tanaka Y, Naitoh S, et al, "Danazol Falsely Increased Values in Estradiol Immunoassays," Clin Chim Acta, 2010, 411(17-18):1380-1. [PubMed 20478287]
  27. Koh WL, Tay YK, Koh MJ. Danazol-induced Stevens-Johnson syndrome in a patient with systemic lupus erythematosus. Dermatol Online J. 2015;21(1):13030/qt24v513b9. Published 2015 Jan 15. [PubMed 25612133]
  28. Kontostolis E, Stefanidis K, Navrozoglou I, Lolis D. Comparison of tamoxifen with danazol for treatment of cyclical mastalgia. Gynecol Endocrinol. 1997;11(6):393-397. [PubMed 9476088]
  29. Lamon JM, Frykholm BC, Herrera W, Tschudy DP. Danazol administration to females with menses-associated exacerbations of acute intermittent porphyria. J Clin Endocrinol Metab. 1979;48(1):123-126. doi:10.1210/jcem-48-1-123 [PubMed 422693]
  30. Laufer MR. Current approaches to optimizing the treatment of endometriosis in adolescents. Gynecol Obstet Invest. 2008;66(Suppl 1):S19-S27. doi:10.1159/000148027 [PubMed 18936548]
  31. Liu W, Gu X, Fu R, et al. The effect of danazol in primary immune thrombocytopenia: an analysis of a large cohort from a single center in China. Clin Appl Thromb Hemost. 2016;22(8):727-733. [PubMed 26681745]
  32. Luciano AA, Hauser KS, Chapler FK, Davis WA, Wallace RB. Effects of danazol on plasma lipid and lipoprotein levels in healthy women and in women with endometriosis. Am J Obstet Gynecol. 1983;145(4):422-426. doi:10.1016/0002-9378(83)90311-3 [PubMed 6824034]
  33. Makdisi WJ, Cherian R, Vanveldhuizen PJ, Talley RL, Stark SP, Dixon AY. Fatal peliosis of the liver and spleen in a patient with agnogenic myeloid metaplasia treated with danazol. Am J Gastroenterol. 1995;90(2):317-318. [PubMed 7847311]
  34. Maloisel F, Andrès E, Zimmer J, et al. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med. 2004;116(9):590-594. [PubMed 15093754]
  35. Mansel RE, Wisbey JR, Hughes LE. Controlled trial of the antigonadotropin danazol in painful nodular benign breast disease. Lancet. 1982;1(8278):928-930. [PubMed 6122770]
  36. Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema: the 2017 revision and update. Allergy. 2018;73(8):1575-1596. doi: 10.1111/all.13384. [PubMed 29318628]
  37. Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema - the 2021 revision and update. World Allergy Organ J. 2022;15(3):100627. doi:10.1016/j.waojou.2022.100627 [PubMed 35497649]
  38. Middleton C, McCaughan GW, Painter DM, Stephen MS, Beale M, Fraser I. Danazol and hepatic neoplasia: a case report. Aust N Z J Med. 1989;19(6):733-735. doi:10.1111/j.1445-5994.1989.tb00350.x [PubMed 2561047]
  39. Milingos DS, Madhuvrata P, Dean J, et al. Hereditary angioedema and pregnancy: successful management of recurrent and frequent attacks of angioedema with C1-inhibitor concentrate, danazol and tranexamic acid - a case report. Obstet Med. 2009;2(3):123-125. doi: 10.1258/om.2009.090003. [PubMed 27582827]
  40. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190-4207. [PubMed 21325604]
  41. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866. doi:10.1182/bloodadvances.2019000966 [PubMed 31794604]
  42. O'Brien PM, Abukhalil IE. Randomized controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase-only danazol. Am J Obstet Gynecol. 1999;180(1, pt 1):18-23. doi:10.1016/s0002-9378(99)70142-0 [PubMed 9914571]
  43. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780-3817. doi:10.1182/bloodadvances.2019000812 [PubMed 31770441]
  44. Qaseem T, Jafri W, Khurshid M, Khan H. Cholestatic jaundice associated with danazol therapy. Postgrad Med J. 1992;68(806):984-985. doi:10.1136/pgmj.68.806.984-a [PubMed 1494534]
  45. Refer to manufacturer's labeling.
  46. Reynolds NJ, Sansom JE. Erythema multiforme during danazol therapy. Clin Exp Dermatol. 1992;17(2):140. doi:10.1111/j.1365-2230.1992.tb00184.x [PubMed 1387593]
  47. Scheckenbach K, Morgan M, Filger-Brillinger J, et al. Treatment of the bone marrow failure in Fanconi anemia patients with danazol. Blood Cells Mol Dis. 2012;48(2):128-131. doi:10.1016/j.bcmd.2011.11.006 [PubMed 22178060]
  48. Sroka I, Frohnmayer L, Van Ravenhorst S, et al, eds. Fanconi anemia clinical care guidelines. 5th edition. Fanconi Anemia Research Fund; 2020. https://www.fanconi.org/images/uploads/other/Fanconi_Anemia_Clinical_Care_Guidelines_5thEdition_web.pdf. Accessed February 18, 2022.
  49. Tan MG, Worley B, Kim WB, Ten Hove M, Beecker J. Drug-induced intracranial hypertension: a systematic review and critical assessment of drug-induced causes [published online November 18, 2019]. Am J Clin Dermatol. 2019. [PubMed 31741184]
  50. Tobiassen T, Rasmussen T, Döberl A, Rannevik G. Danazol treatment of severely symptomatic fibrocystic breast disease and long-term follow-up—the Hjørring project. Acta Obstet Gynecol Scand Suppl. 1984;123:159-176. doi:10.3109/00016348409157006 [PubMed 6594009]
  51. Vesely SK, Perdue JJ, Rizvi MA, Terrell DR, George JN. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review. Ann Intern Med. 2004;140(2):112-120. [PubMed 14734334]
  52. Williams G, Lofts F, Fuessl H, Bloom S. Treatment with danazol and plasma glucagon concentration. Br Med J (Clin Res Ed). 1985;291(6503):1155-1156. doi:10.1136/bmj.291.6503.1155 [PubMed 3931833]
  53. Yamamoto K, Hoshiai H, Tsubaki K, Kasano Y, Shimizu K, Horiuchi A. Danazol induced thrombocytopenia. Tohoku J Exp Med. 1997;182(3):249-252. doi:10.1620/tjem.182.249 [PubMed 9362107]
  54. Zawar V, Sankalecha C. Facial hirsutism following danazol therapy. Cutis. 2004;74(5):301-303. [PubMed 15605967]
  55. Zimmer J, Andres E, Noel E, Koumarianou A, Blickle JF, Maloisel F. Current management of adult idiopathic thrombocytopenic purpura in practice: a cohort study of 201 patients from a single center. Clin Lab Haem. 2004;26(2):137-142. [PubMed 15053808]
  56. Zuraw BL, Banerji A, Bernstein JA, et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol Pract. 2013a;1(5):458-467. [PubMed 24565617]
  57. Zuraw BL, Bernstein JA, Lang DM, et al. A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema. J Allergy Clin Immunol. 2013b;131(6):1491-1493. [PubMed 23726531]
Topic 13199 Version 206.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟